DIMERIX LIMITED - Announcements

1.05%

47.0¢

Market Cap $282.0M

Healthcare Biotechnology

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

DXB	New Clinical Trial for DMX-200 in Diabetic Kidney Disease	PRICE SENSITIVE	07/06/22	287.61KB	Share
DXB	Dimerix to Present at BIO International Convention		06/06/22	7.62MB	Share
DXB	Phase 3 FSGS Kidney Trial First Patient Recruited	PRICE SENSITIVE	31/05/22	362.33KB	Share
DXB	Release of Shares from Voluntary Escrow		18/05/22	154.08KB	Share
DXB	Dimerix presentation at Bioshares Biotech Summit	PRICE SENSITIVE	12/05/22	4.15MB	Share
DXB	FDA IND Approval for Phase 3 Study of DMX-200 in FSGS	PRICE SENSITIVE	09/05/22	305.47KB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	27/04/22	634.84KB	Share
DXB	Dimerix Receives A$3.7M R&D Tax Incentive Rebate	PRICE SENSITIVE	29/03/22	315.38KB	Share
DXB	Investor Presentation		29/03/22	5.3MB	Share
DXB	Dimerix Investor Call and Presentation		01/03/22	2.74MB	Share
DXB	DSMB Change to REMAP-CAP COVID-19 Study	PRICE SENSITIVE	28/02/22	300.56KB	Share
DXB	Investor Presentation		24/02/22	4.85MB	Share
DXB	Half-Year Financial Report & Appendix 4D - 31 December 2021	PRICE SENSITIVE	24/02/22	927.83KB	Share
DXB	Dimerix Appoints Chief Medical Officer		07/02/22	298.7KB	Share
DXB	First Regulatory Approval in Europe for DMX-200 FSGS Study	PRICE SENSITIVE	01/02/22	305.98KB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	28/01/22	517.61KB	Share
DXB	Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India	PRICE SENSITIVE	11/01/22	463.32KB	Share
DXB	Ethics Approval in Australia for Phase 3 COVID-19 Study	PRICE SENSITIVE	23/12/21	344.65KB	Share
DXB	Dimerix Receives Further MRFF Funding for DMX-200		22/12/21	379.75KB	Share
DXB	DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe	PRICE SENSITIVE	16/12/21	336.58KB	Share
DXB	Pause in Trading	PRICE SENSITIVE	16/12/21	113.2KB	Share
DXB	Notification regarding unquoted securities - DXB		06/12/21	24.88KB	Share
DXB	Investor Presentation		23/11/21	2.82MB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	25/10/21	594.78KB	Share
DXB	First Approvals Received for Start of Phase 3 FSGS Trial	PRICE SENSITIVE	21/10/21	333.01KB	Share
DXB	Phase 3 DMX-200 COVID-19 Study Expands into Australia	PRICE SENSITIVE	15/10/21	346.69KB	Share
DXB	Change in substantial holding		07/10/21	1.38MB	Share
DXB	Becoming a substantial holder		05/10/21	225.86KB	Share
DXB	Secondary Trading Notice Pursuant to Section 708A(5)(e)		05/10/21	365.79KB	Share
DXB	Change of Director's Interest Notices - JW, HA, SP and NW		05/10/21	329.47KB	Share
DXB	Notification regarding unquoted securities - DXB		05/10/21	25.93KB	Share
DXB	Notification regarding unquoted securities - DXB		05/10/21	23.59KB	Share
DXB	Notification regarding unquoted securities - DXB		05/10/21	26.06KB	Share
DXB	Notification regarding unquoted securities - DXB		05/10/21	23.54KB	Share
DXB	Application for quotation of securities - DXB		05/10/21	24.63KB	Share
DXB	Application for quotation of securities - DXB		05/10/21	24.7KB	Share
DXB	Dimerix Closes SPP Oversubscribed	PRICE SENSITIVE	01/10/21	317.3KB	Share
DXB	Results of Meeting		27/09/21	399.72KB	Share
DXB	AGM Presentation		27/09/21	2.77MB	Share
DXB	CEO's Address to Shareholders		27/09/21	1.29MB	Share
DXB	Virtual Meeting Voting and Registration Guide		27/09/21	470.95KB	Share
DXB	DMX-200 CLARITY COVID-19 Study Approval in India	PRICE SENSITIVE	24/09/21	349.78KB	Share
DXB	Change of Director's Interest Notices - JW, HA and SP		15/09/21	888.92KB	Share
DXB	Change in substantial holding		03/09/21	133.54KB	Share
DXB	Phase 3 Study in FSGS Kidney Patients Commences	PRICE SENSITIVE	25/08/21	255.95KB	Share
DXB	Notice of Annual General Meeting/Proxy Form		24/08/21	729.53KB	Share
DXB	Annual General Meeting - Notice and Letter to Shareholders		24/08/21	503.11KB	Share
DXB	SPP and Options Prospectus	PRICE SENSITIVE	24/08/21	665.62KB	Share
DXB	Secondary Trading Notice Pursuant to Section 708A(5)(e)		24/08/21	359.14KB	Share
DXB	Application for quotation of securities - DXB		24/08/21	24.74KB	Share
DXB	Application for quotation of securities - DXB		24/08/21	24.81KB	Share
DXB	Response to ASX Query	PRICE SENSITIVE	19/08/21	303.57KB	Share
DXB	Secondary Trading Notice Pursuant to Section 708A(5)(e)		18/08/21	369.19KB	Share
DXB	Application for quotation of securities - DXB		18/08/21	24.64KB	Share
DXB	Investor Presentation		16/08/21	4.39MB	Share
DXB	Appendix 4G and Corporate Governance Statement		16/08/21	483.1KB	Share
DXB	Annual Report to Shareholders		16/08/21	2.48MB	Share
DXB	Preliminary Final Report	PRICE SENSITIVE	16/08/21	262.19KB	Share
DXB	Proposed issue of securities - DXB		16/08/21	25.11KB	Share
DXB	Proposed issue of securities - DXB		16/08/21	26.92KB	Share
DXB	Proposed issue of securities - DXB		16/08/21	32.8KB	Share
DXB	Proposed issue of securities - DXB		16/08/21	30.64KB	Share
DXB	Successful $20m Placement to Fund Phase 3 Trials	PRICE SENSITIVE	16/08/21	315.83KB	Share
DXB	Trading Halt	PRICE SENSITIVE	12/08/21	363.81KB	Share
DXB	DMX-200 COVID-19 Study Opens More Sites in Europe and UK	PRICE SENSITIVE	02/08/21	308.9KB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	27/07/21	511.42KB	Share
DXB	FDA Confirms Phase 3 Study Design in FSGS Kidney Disease	PRICE SENSITIVE	19/07/21	270.67KB	Share
DXB	Dimerix Receives Innovation Passport and ILAP Designation	PRICE SENSITIVE	07/06/21	274.83KB	Share
DXB	Dimerix Confirms Phase 3 FSGS Study Design With EMA	PRICE SENSITIVE	03/06/21	297.79KB	Share
DXB	DMX-200 Remains Eligible for Accelerated Approval	PRICE SENSITIVE	27/05/21	280.56KB	Share
DXB	Investor Presentation		25/05/21	5.09MB	Share
DXB	Update of DMX-200 Study in COVID-19 Patients in India		12/05/21	255.17KB	Share
DXB	COVID-19 Study Recruits Multiple Patients in Europe	PRICE SENSITIVE	23/04/21	308.13KB	Share
DXB	Notification of Expired Options		21/04/21	259.22KB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	08/04/21	586.68KB	Share
DXB	Major Shareholder Loan for $5 Million	PRICE SENSITIVE	30/03/21	282.98KB	Share
DXB	Investor Presentation		29/03/21	5.21MB	Share
DXB	Clinical Study in Patients with COVID-19 Progresses	PRICE SENSITIVE	25/03/21	303.04KB	Share
DXB	DMX-200 Competitive Position Further Enhanced	PRICE SENSITIVE	24/03/21	256.2KB	Share
DXB	Lapse of Unlisted Options		17/03/21	259.39KB	Share
DXB	CLARITY 2.0 Study Progresses In Patients With COVID-19	PRICE SENSITIVE	10/03/21	289.02KB	Share
DXB	Secondary Trading Notice Pursuant to Section 708A(5)(e)		23/02/21	357.05KB	Share
DXB	Appendix 2A		23/02/21	284.45KB	Share
DXB	Half Year Report and Update		22/02/21	290.17KB	Share
DXB	Appendix 4D and Interim Financial Report	PRICE SENSITIVE	22/02/21	956.04KB	Share
DXB	Dimerix Plans for Next Study in Diabetic Kidney Disease	PRICE SENSITIVE	28/01/21	406.67KB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	22/01/21	569.96KB	Share
DXB	Investor Presentation		16/12/20	4.15MB	Share
DXB	Second Study to Include DMX-200 in COVID-19 Patients	PRICE SENSITIVE	30/11/20	236.94KB	Share
DXB	Notification of Expired Options		16/11/20	350.88KB	Share
DXB	ARDS in COVID-19 Patients Protocol Published	PRICE SENSITIVE	09/11/20	234.24KB	Share
DXB	Secondary Trading Notice Pursuant to Section 708A(5)(e)		27/10/20	484.74KB	Share
DXB	Appendix 2A		27/10/20	234.45KB	Share
DXB	Positive Additional Data to Support DMX-200 Development	PRICE SENSITIVE	27/10/20	3.7MB	Share
DXB	Quarterly Appendix 4C and Activities Report	PRICE SENSITIVE	23/10/20	662.36KB	Share
DXB	Receipt of R&D Tax Incentive	PRICE SENSITIVE	21/10/20	282.29KB	Share
DXB	Shareholder Update		20/10/20	547.16KB	Share
DXB	DMX-700 Data Demonstrates Effect on Key COPD Receptors	PRICE SENSITIVE	07/10/20	335.48KB	Share
DXB	Amended Constitution		30/09/20	824.81KB	Share
DXB	Results of Meeting		30/09/20	396.94KB	Share

DXB New Clinical Trial for DMX-200 in Diabetic Kidney Disease
07/06/22	PRICE SENSITIVE	287.61KB	Share
DXB Dimerix to Present at BIO International Convention
06/06/22		7.62MB	Share
DXB Phase 3 FSGS Kidney Trial First Patient Recruited
31/05/22	PRICE SENSITIVE	362.33KB	Share
DXB Release of Shares from Voluntary Escrow
18/05/22		154.08KB	Share
DXB Dimerix presentation at Bioshares Biotech Summit
12/05/22	PRICE SENSITIVE	4.15MB	Share
DXB FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
09/05/22	PRICE SENSITIVE	305.47KB	Share
DXB Quarterly Appendix 4C and Activities Report
27/04/22	PRICE SENSITIVE	634.84KB	Share
DXB Dimerix Receives A$3.7M R&D Tax Incentive Rebate
29/03/22	PRICE SENSITIVE	315.38KB	Share
DXB Investor Presentation
29/03/22		5.3MB	Share
DXB Dimerix Investor Call and Presentation
01/03/22		2.74MB	Share
DXB DSMB Change to REMAP-CAP COVID-19 Study
28/02/22	PRICE SENSITIVE	300.56KB	Share
DXB Investor Presentation
24/02/22		4.85MB	Share
DXB Half-Year Financial Report & Appendix 4D - 31 December 2021
24/02/22	PRICE SENSITIVE	927.83KB	Share
DXB Dimerix Appoints Chief Medical Officer
07/02/22		298.7KB	Share
DXB First Regulatory Approval in Europe for DMX-200 FSGS Study
01/02/22	PRICE SENSITIVE	305.98KB	Share
DXB Quarterly Appendix 4C and Activities Report
28/01/22	PRICE SENSITIVE	517.61KB	Share
DXB Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
11/01/22	PRICE SENSITIVE	463.32KB	Share
DXB Ethics Approval in Australia for Phase 3 COVID-19 Study
23/12/21	PRICE SENSITIVE	344.65KB	Share
DXB Dimerix Receives Further MRFF Funding for DMX-200
22/12/21		379.75KB	Share
DXB DSMB Recommends Continuation of Ph3 COVID-19 Study in Europe
16/12/21	PRICE SENSITIVE	336.58KB	Share
DXB Pause in Trading
16/12/21	PRICE SENSITIVE	113.2KB	Share
DXB Notification regarding unquoted securities - DXB
06/12/21		24.88KB	Share
DXB Investor Presentation
23/11/21		2.82MB	Share
DXB Quarterly Appendix 4C and Activities Report
25/10/21	PRICE SENSITIVE	594.78KB	Share
DXB First Approvals Received for Start of Phase 3 FSGS Trial
21/10/21	PRICE SENSITIVE	333.01KB	Share
DXB Phase 3 DMX-200 COVID-19 Study Expands into Australia
15/10/21	PRICE SENSITIVE	346.69KB	Share
DXB Change in substantial holding
07/10/21		1.38MB	Share
DXB Becoming a substantial holder
05/10/21		225.86KB	Share
DXB Secondary Trading Notice Pursuant to Section 708A(5)(e)
05/10/21		365.79KB	Share
DXB Change of Director's Interest Notices - JW, HA, SP and NW
05/10/21		329.47KB	Share
DXB Notification regarding unquoted securities - DXB
05/10/21		25.93KB	Share
DXB Notification regarding unquoted securities - DXB
05/10/21		23.59KB	Share
DXB Notification regarding unquoted securities - DXB
05/10/21		26.06KB	Share
DXB Notification regarding unquoted securities - DXB
05/10/21		23.54KB	Share
DXB Application for quotation of securities - DXB
05/10/21		24.63KB	Share
DXB Application for quotation of securities - DXB
05/10/21		24.7KB	Share
DXB Dimerix Closes SPP Oversubscribed
01/10/21	PRICE SENSITIVE	317.3KB	Share
DXB Results of Meeting
27/09/21		399.72KB	Share
DXB AGM Presentation
27/09/21		2.77MB	Share
DXB CEO's Address to Shareholders
27/09/21		1.29MB	Share
DXB Virtual Meeting Voting and Registration Guide
27/09/21		470.95KB	Share
DXB DMX-200 CLARITY COVID-19 Study Approval in India
24/09/21	PRICE SENSITIVE	349.78KB	Share
DXB Change of Director's Interest Notices - JW, HA and SP
15/09/21		888.92KB	Share
DXB Change in substantial holding
03/09/21		133.54KB	Share
DXB Phase 3 Study in FSGS Kidney Patients Commences
25/08/21	PRICE SENSITIVE	255.95KB	Share
DXB Notice of Annual General Meeting/Proxy Form
24/08/21		729.53KB	Share
DXB Annual General Meeting - Notice and Letter to Shareholders
24/08/21		503.11KB	Share
DXB SPP and Options Prospectus
24/08/21	PRICE SENSITIVE	665.62KB	Share
DXB Secondary Trading Notice Pursuant to Section 708A(5)(e)
24/08/21		359.14KB	Share
DXB Application for quotation of securities - DXB
24/08/21		24.74KB	Share
DXB Application for quotation of securities - DXB
24/08/21		24.81KB	Share
DXB Response to ASX Query
19/08/21	PRICE SENSITIVE	303.57KB	Share
DXB Secondary Trading Notice Pursuant to Section 708A(5)(e)
18/08/21		369.19KB	Share
DXB Application for quotation of securities - DXB
18/08/21		24.64KB	Share
DXB Investor Presentation
16/08/21		4.39MB	Share
DXB Appendix 4G and Corporate Governance Statement
16/08/21		483.1KB	Share
DXB Annual Report to Shareholders
16/08/21		2.48MB	Share
DXB Preliminary Final Report
16/08/21	PRICE SENSITIVE	262.19KB	Share
DXB Proposed issue of securities - DXB
16/08/21		25.11KB	Share
DXB Proposed issue of securities - DXB
16/08/21		26.92KB	Share
DXB Proposed issue of securities - DXB
16/08/21		32.8KB	Share
DXB Proposed issue of securities - DXB
16/08/21		30.64KB	Share
DXB Successful $20m Placement to Fund Phase 3 Trials
16/08/21	PRICE SENSITIVE	315.83KB	Share
DXB Trading Halt
12/08/21	PRICE SENSITIVE	363.81KB	Share
DXB DMX-200 COVID-19 Study Opens More Sites in Europe and UK
02/08/21	PRICE SENSITIVE	308.9KB	Share
DXB Quarterly Appendix 4C and Activities Report
27/07/21	PRICE SENSITIVE	511.42KB	Share
DXB FDA Confirms Phase 3 Study Design in FSGS Kidney Disease
19/07/21	PRICE SENSITIVE	270.67KB	Share
DXB Dimerix Receives Innovation Passport and ILAP Designation
07/06/21	PRICE SENSITIVE	274.83KB	Share
DXB Dimerix Confirms Phase 3 FSGS Study Design With EMA
03/06/21	PRICE SENSITIVE	297.79KB	Share
DXB DMX-200 Remains Eligible for Accelerated Approval
27/05/21	PRICE SENSITIVE	280.56KB	Share
DXB Investor Presentation
25/05/21		5.09MB	Share
DXB Update of DMX-200 Study in COVID-19 Patients in India
12/05/21		255.17KB	Share
DXB COVID-19 Study Recruits Multiple Patients in Europe
23/04/21	PRICE SENSITIVE	308.13KB	Share
DXB Notification of Expired Options
21/04/21		259.22KB	Share
DXB Quarterly Appendix 4C and Activities Report
08/04/21	PRICE SENSITIVE	586.68KB	Share
DXB Major Shareholder Loan for $5 Million
30/03/21	PRICE SENSITIVE	282.98KB	Share
DXB Investor Presentation
29/03/21		5.21MB	Share
DXB Clinical Study in Patients with COVID-19 Progresses
25/03/21	PRICE SENSITIVE	303.04KB	Share
DXB DMX-200 Competitive Position Further Enhanced
24/03/21	PRICE SENSITIVE	256.2KB	Share
DXB Lapse of Unlisted Options
17/03/21		259.39KB	Share
DXB CLARITY 2.0 Study Progresses In Patients With COVID-19
10/03/21	PRICE SENSITIVE	289.02KB	Share
DXB Secondary Trading Notice Pursuant to Section 708A(5)(e)
23/02/21		357.05KB	Share
DXB Appendix 2A
23/02/21		284.45KB	Share
DXB Half Year Report and Update
22/02/21		290.17KB	Share
DXB Appendix 4D and Interim Financial Report
22/02/21	PRICE SENSITIVE	956.04KB	Share
DXB Dimerix Plans for Next Study in Diabetic Kidney Disease
28/01/21	PRICE SENSITIVE	406.67KB	Share
DXB Quarterly Appendix 4C and Activities Report
22/01/21	PRICE SENSITIVE	569.96KB	Share
DXB Investor Presentation
16/12/20		4.15MB	Share
DXB Second Study to Include DMX-200 in COVID-19 Patients
30/11/20	PRICE SENSITIVE	236.94KB	Share
DXB Notification of Expired Options
16/11/20		350.88KB	Share
DXB ARDS in COVID-19 Patients Protocol Published
09/11/20	PRICE SENSITIVE	234.24KB	Share
DXB Secondary Trading Notice Pursuant to Section 708A(5)(e)
27/10/20		484.74KB	Share
DXB Appendix 2A
27/10/20		234.45KB	Share
DXB Positive Additional Data to Support DMX-200 Development
27/10/20	PRICE SENSITIVE	3.7MB	Share
DXB Quarterly Appendix 4C and Activities Report
23/10/20	PRICE SENSITIVE	662.36KB	Share
DXB Receipt of R&D Tax Incentive
21/10/20	PRICE SENSITIVE	282.29KB	Share
DXB Shareholder Update
20/10/20		547.16KB	Share
DXB DMX-700 Data Demonstrates Effect on Key COPD Receptors
07/10/20	PRICE SENSITIVE	335.48KB	Share
DXB Amended Constitution
30/09/20		824.81KB	Share
DXB Results of Meeting
30/09/20		396.94KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 47.0¢		Change -0.005(1.05%)		Mkt cap ! $282.0M

Open	High	Low	Value	Volume
47.0¢	49.3¢	46.5¢	$1.188M	2.509M

Buyers (Bids)

No.	Vol.	Price($)
3	28330	47.0¢

Sellers (Offers)

Price($)	Vol.	No.
49.0¢	48233	4

View Market Depth

No.	Vol.	Price($)
3	28330	0.470
7	57251	0.465
14	406384	0.460
8	244524	0.455
13	154471	0.450

Price($)	Vol.	No.
0.490	48233	4
0.495	29716	3
0.500	3688	2
0.505	58000	3
0.520	44400	2

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last 47.0¢		Change -0.005 ( 1.67 %)
Open	High	Low	Volume
47.0¢	48.5¢	46.5¢	960457
Last updated 15.55pm 31/07/2025 ?

DXB (ASX) Chart

DIMERIX LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories